Doesn't it look beautiful? Absolutely stunning. From the...

Doesn't it look beautiful? Absolutely stunning.

From the announcement 24th of  Octobber...

This marks the beginning of Admedus’ entry into the $3 billion global TAVR market (projected to be $5 billion by 2020) which offers an alternative treatment option for patients who are unsuitable candidates for surgical heart valve replacement or repair.

Both new innovations offer significant improvements in product quality and efficiency as well as reduced manufacturing costs and health benefits to patients.

Admedus has developed a novel process to package and ship the TAVR components in sterile fluid that preserves the integrity of the valve and sterilises the catheter, enabling surgeons to use the product in a more efficient single-step process. The hydro-packaging would allow for the replacement valve and catheter to be supplied in sterile ‘wet packs’ that are ready for immediate use – substantially reducing the time required for assembly preparation.

When manufacturing TAVR devices, one of the most time-consuming and labor-intensive portions of the process is attaching multiple leaflets securely to the stent. Admedus will solve this problem by creating a three dimensional, single-piece molded valve that uses three leaflets in a single scaffold and securely attaches to a stent with minimal sutures.
By reducing the amount of suturing required to attach the valve to the stent 10-fold, Admedus will be able to reduce the cost of manufacturing the TAVR.